Published as a subscription-based publication for more than 30 years, The Helper is now available free online. 17 (HealthDay News) — Today’s teens may be at higher risk than ever of contracting genital herpes because they don’t have enough immune system antibodies to shield them against the sexually transmitted virus, a new study suggests. Individuals with herpes have reported seemingly unrelated symptoms such as constipation and urinary retention (inability to empty the bladder), but the mechanism was not understood. The partnership entitles Array to receive an upfront payment of $12 million, and up $64 million if certain development and commercialization milestones are achieved, and is eligible for up to double-digit royalties. Cardiovascular Systems Inc. Karim said: “The overall incidence rate of 15.5 cases per 100 person-years means that if 1 000 persons who were herpes simplex virus- (HSV) 2-negative at the beginning of the year were tested one year later, 155 of these people would be HSV-2 positive. More of those women went on to have Caesarean sections than did those given valacyclovir, which the body breaks down to form the herpes drug acyclovir.
are diagnosed with herpes every year. According to the company, BRAND A tobacco cigarettes contain less than 0.6 mg nicotine per cigarette and less than 0.05 mg nicotine yield per cigarette – a reduction in nicotine of at least 95% as compared to conventional cigarettes. Shares of Genocea Biosciences Inc. HSV-1 is usually contracted in childhood, by skin-to-skin contact with an infected adult, whereas HSV-2 is most often sexually transmitted. According to the trial results, GEN-003 demonstrated sustained and statistically significant reductions compared to baseline in the rate of viral shedding 12 months after dosing across multiple dose groups as well as sustained efficacy at multiple dose levels across secondary endpoints measuring the impact on clinical disease. GEN-003 was safe and well tolerated by patients, with no serious adverse events related to the vaccine in the trial. A phase IIb study of GEN-003 in genital herpes is underway, and virologic efficacy data from this trial is expected to be reported in the third quarter of 2016 while clinical efficacy data at 6 months post dosing is expected around the end of 2016.
The name change is said to reflect the evolution of the company’s focus from commercializing bioreactors and research tools to the pioneering development of bioengineered organ implants for the esophagus, bronchus, and trachea. Wendel and his colleagues also published a rebuttal in the journal, saying in part that the study balanced the risks and benefits of valacyclovir to both the mothers and their fetuses. The free service allows users to talk with and meet individuals who understand and share their condition. Annualized relapse rate at 24 weeks compared favorably with previously reported pivotal studies of interferon beta-1a therapies Avonex and Rebif.